# US 2010/0168244 A1 · Naphthalene compounds, a process for their preparation and pharmaceutical compositions containing them

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0168244 A1
- Document ID: US20100168244A1
- Status: Published application
- Kind: A1
- Application number: 12/452,429
- Filed: 2008-07-01
- Published: 2010-07-01
- Earliest claimed: 2007-07-02
- Assignees: Less Laboratoires Servier
- Inventors: Said Yous; Mohamed Ettaoussi; Ahmed Sabaouni; Pascal Berthelot; Michael Spedding; Philippe Delagrange; Daniel-Henri Caignard; Mark Millan
- Web page: https://patentgrep.com/patent/US20100168244A1

## CPC

- C07C 251/48: with the carbon atom of at least one of the oxyimino groups bound to a carbon atom of a six-membered aromatic ring
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 15/08: for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A61P 15/10: for impotence
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/06: Antimigraine agents
- A61P 25/08: Antiepileptics; Anticonvulsants
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/18: Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A61P 25/20: Hypnotics; Sedatives
- A61P 25/22: Anxiolytics
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07C: ACYCLIC OR CARBOCYCLIC COMPOUNDS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Compounds of formula (I): wherein: R1 represents alkyl, alkenyl, haloalkyl, polyhaloalkyl, cycloalkyl, cycloalkylalkyl, aryl, arylalkyl, heteroaryl or heteroarylalkyl, X represents a group N—OR2 wherein R2 represents a hydrogen atom or an alkyl group. Medicinal products containing the same which are useful in treating disorders of the melatoninergic system.

## Claims

### Claim at position 1

1-9. (canceled)

### Claim at position 2

10- A compound selected from those of formula (I):
wherein:
R1 represents a linear or branched (C1-C6)alkyl group, a linear or branched (C1-C6)alkenyl group, a linear or branched (C1-C6)haloalkyl group, a linear or branched (C1-C6)polyhaloalkyl group, a (C3-C8)cycloalkyl group, a (C3-C8)cycloalkyl-(C1-C6)alkyl group in which the alkyl moiety may be linear or branched, an aryl group, an aryl-(C1-C6)alkyl group in which the alkyl moiety may be linear or branched, a heteroaryl group or a heteroaryl-(C1-C6)alkyl group in which the alkyl moiety may be linear or branched,
X represents a N—OR2 group wherein R2 represents a hydrogen atom or a linear or branched (C1-C6)alkyl group,
it being understood that:
the oxime ═N—OR2 may be of Z or E configuration,
“aryl” means phenyl, naphthyl or biphenyl,
“heteroaryl” means a mono- or bi-cyclic aromatic group having from 1 to 3 hetero atoms selected from oxygen, sulphur and nitrogen,
wherein the aryl and heteroaryl groups may be optionally substituted by 1 to 3 groups selected from linear or branched (C1-C6)alkyl, linear or branched (C1-C6)alkoxy, hydroxy, carboxy, formyl, nitro, cyano, linear or branched (C1-C6)haloalkyl, linear or branched (C1-C6)polyhaloalkyl, alkyloxycarbonyl and halogen,
and enantiomers, diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base.

### Claim at position 3 (depends on 10)

11- The compound of claim 10, wherein R1 represents a linear or branched (C1-C6)alkyl group.

### Claim at position 4 (depends on 10)

12- The compound of claim 10, wherein R2 represents a methyl group.

### Claim at position 5 (depends on 10)

13- The compound of claim 10, wherein R2 represents a hydrogen atom.

### Claim at position 6 (depends on 10)

14- The compound of claim 10, which is N-[(2E)-2-(hydroxyimino)-2-(7-methoxy-1-naphthyl)ethyl]acetamide, or an addition salt thereof with a pharmaceutically acceptable base.

### Claim at position 7 (depends on 10)

15- A pharmaceutical composition comprising at least one compound of claim 10, or an addition salt thereof with a pharmaceutically acceptable base, in combination with one or more pharmaceutically acceptable excipients.

### Claim at position 8 (depends on 10)

16- A method for treating a living animal body, including a human, afflicted with a disorder of the melatoninergic system, comprising the step of administering to the living animal body, including a human, a therapeutically effective amount of the compound of claim 10.

### Claim at position 9 (depends on 10)

17- A method for treating a living animal body, including a human, afflicted with a condition selected from sleep disorders, stress, anxiety, major depression or seasonal affective disorder, cardiovascular pathologies, pathologies of the digestive system, insomnia and fatigue due to jetlag, schizophrenia, panic attacks, melancholia, appetite disorders, obesity, insomnia, psychotic disorders, epilepsy, diabetes, Parkinson's disease, senile dementia, various disorders associated with normal or pathological ageing, migraine, memory loss, Alzheimer's disease, cerebral circulation disorders, sexual dysfunction, a condition requiring an ovulation inhibitor, a condition requiring an immunomodulator, and cancer, comprising the step of administering to the living animal body, including a human, a therapeutically effective amount of the compound of claim 10.